Ebola Virus Infection Medication

Updated: Jan 14, 2021
  • Author: John W King, MD; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD  more...
  • Print
Medication

Medication Summary

A vaccine is approved for prevention of disease caused by Zaire ebolavirus in patients aged 18 years or older. A recombinant human monoclonal antibody and combination product of 3 monoclonal antibodies have been approved for treatment in adults and children, including neonates. 

Next:

Monoclonal Antibodies

Class Summary

Antibodies that bind to the Zaire ebolavirus glycoprotein and help neutralize the virus.

Atoltivimab/maftivimab/odesivimab (Inmazeb)

The 3 antibodies bind to different, nonoverlapping epitopes on the Zaire ebolavirus glycoprotein. It is indicated for treatment of Zaire ebolavirus in adults and children, including neonates born to a mother who is reverse-transcriptase polymerase chain reaction (RT-PCR) positive for Zaire ebolavirus infection.

Ansuvimab (Ebanga, Ansuvimab-zykl)

A human recombinant monoclonal antibody blocks binding of the virus to the cell receptor, preventing its entry into the cell. It is indicated for treatment of Zaire ebolavirus in adults and children, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.

Previous
Next:

Vaccines, Live, Viral

Class Summary

Elicits immune response to specific ebolavirus strain.

Ebola Zaire vaccine (Ervebo)

Recombinant vesicular stomatitis virus-Zaire ebolavirus (rVSV-ZEBOV; V920) is a replication-competent vaccine. It is genetically engineered to express a glycoprotein from Zaire ebolavirus to provoke a neutralizing immune response to the Ebola virus. It is indicated for prevention of disease caused by Zaire ebolavirus.

Previous